Daily Newsletter

15 August 2023

Share with colleague
Subscribe

Daily Newsletter

15 August 2023

Share with colleague
Subscribe

Spotlight

Arcellx resumes pivotal Phase II CAR-T trial in myeloma

Arcellx plans to present topline data in H2 2024, with the anticipated commercial launch of CART-ddBCMA in 2026.

Latest news

Eloxx reports all patients in Phase II Alport syndrome trial have improved

Eloxx Pharmaceuticals has reported that all patients in the Phase II trial showed improvement in podocyte foot process effacement.

15 August 2023

Sandoz plans to enter the Eylea biosimilar race

Sandoz is to file for regulatory approval following positive Phase III results in wet macular degeneration.

15 August 2023

Further clinical success for Anteris Technologies’ biomimetic heart valve

A second valve-in-valve case adds to two early feasibility studies being conducted in the US and Europe for the device.

15 August 2023

First patient dosed in Phase IIb RewinD-LB trial for DLB

The Phase IIb trial comes after DLB patients showed improvements in dementia severity and motor function in Phase IIa of neflamapimod.

15 August 2023

FDA grants clearance to Zumutor’s IND for solid cancer drug trial

The first-in-human study will determine the recommended Phase II dose.

15 August 2023

vTv gears up for FDA approval for cadisegliatin in type 1 diabetes

vTv plans to initiate a Phase III study with an FDA-recommended primary endpoint by the end of 2023.

15 August 2023

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.